Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Ligand-Gated Ion Channel Receptor: Gating Mechanism01:30

Ligand-Gated Ion Channel Receptor: Gating Mechanism

2.4K
Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
2.4K
Amyloid Fibrils03:03

Amyloid Fibrils

9.7K
Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining,...
9.7K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

234
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
234

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Glycoengineered Host-Guest Nanoparticles Potentiate Alzheimer's Disease Therapy via Lesion-Specific Modulation of Tau Pathology.

Journal of the American Chemical Society·2026
Same author

Artemverlotolides A and B, Two Sesquiterpenes from <i>Artemisia verlotorum</i> Lamotte: Structural Elucidation, Bioinspired Synthesis, and Antineuroinflammatory Activity.

Organic letters·2026
Same author

Correction to "Kinetics-Driven Drug Design Strategy for Next-Generation Acetylcholinesterase Inhibitors to Clinical Candidate".

Journal of medicinal chemistry·2025
Same author

Benzbromarone interferes with the interaction between Hsp90 and Aha1 by interacting with both of them.

Communications biology·2025
Same author

Sertraline and Astemizole Enhance the Deubiquitinase Activity of USP7 by Binding to Its Switching Loop Region.

Journal of medicinal chemistry·2025
Same author

Uncommon Diterpenoids with Diverse Frameworks from the South China Sea Sponge <i>Spongia officinalis</i> and Their Anti-inflammatory Activities.

The Journal of organic chemistry·2025

Related Experiment Video

Updated: Aug 8, 2025

A11-positive &#946;-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis
06:17

A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis

Published on: May 22, 2018

12.0K

Sodium Oligomannate Electrostatically Binds to Aβ and Blocks Its Aggregation.

Chen Zhou1, Jingjing Zhang2,3, Xinwen Luo1,4

  • 1Analytical Research Center for Organic and Biological Molecules, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai 201203, China.

The Journal of Physical Chemistry. B
|February 27, 2023
PubMed
Summary

GV-971 (sodium oligomannate) inhibits Alzheimer's disease-related amyloid-beta (Aβ) aggregation. Its carboxylic groups interact with Aβ histidines, breaking aggregation pathways and protecting against Aβ fibril formation.

More Related Videos

Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps
10:19

Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps

Published on: August 14, 2016

9.3K
Preparation of Oligomeric &#946;-amyloid1-42 and Induction of Synaptic Plasticity Impairment on Hippocampal Slices
04:41

Preparation of Oligomeric β-amyloid1-42 and Induction of Synaptic Plasticity Impairment on Hippocampal Slices

Published on: July 14, 2010

23.3K

Related Experiment Videos

Last Updated: Aug 8, 2025

A11-positive &#946;-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis
06:17

A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis

Published on: May 22, 2018

12.0K
Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps
10:19

Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps

Published on: August 14, 2016

9.3K
Preparation of Oligomeric &#946;-amyloid1-42 and Induction of Synaptic Plasticity Impairment on Hippocampal Slices
04:41

Preparation of Oligomeric β-amyloid1-42 and Induction of Synaptic Plasticity Impairment on Hippocampal Slices

Published on: July 14, 2010

23.3K

Area of Science:

  • Biochemistry
  • Biophysics
  • Neuroscience

Background:

  • GV-971 (sodium oligomannate) is approved in China for Alzheimer's disease treatment.
  • GV-971 has demonstrated inhibition of amyloid-beta (Aβ) fibril formation in vitro and in vivo.
  • Understanding the precise molecular mechanisms of GV-971's action on Aβ aggregation is crucial.

Purpose of the Study:

  • To elucidate the molecular mechanisms by which GV-971 modulates Aβ40 and Aβ42 aggregation.
  • To investigate the role of electrostatic interactions and dynamics in the GV-971-Aβ binding.
  • To provide a detailed biochemical and biophysical characterization of the Aβ40/Aβ42:GV-971 system.

Main Methods:

  • Systematic biochemical and biophysical analysis of Aβ40/Aβ42:GV-971 systems.
  • Integration of previously published data with new experimental results.
  • Analysis of electrostatic interactions and conformational flexibility.

Main Results:

  • Multisite electrostatic interactions between GV-971's carboxylic groups and Aβ's histidine residues are key to GV-971 binding.
  • GV-971 binding likely protects Aβ from aggregation by disrupting histidine-mediated inter-Aβ electrostatic interactions.
  • A minor role for dynamics alteration in GV-971's modulation of Aβ aggregation was observed.

Conclusions:

  • GV-971's primary mechanism involves electrostatic interactions with Aβ histidines, preventing aggregation.
  • The drug's effect on Aβ dynamics plays a secondary role in its anti-aggregation activity.
  • These findings enhance the understanding of GV-971's therapeutic potential for Alzheimer's disease.